Patients interested in learning more about JUVÉDERM ® VOLUMA ® XC for temple hollowing are encouraged to enroll in Allē, the Allergan Aesthetics loyalty rewards program. In serving more than seven ...
At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
(RTTNews) - Allergan plc (AGN) said that it received U.S. Food and Drug Administration approval for the use of Juvéderm VOLUMA XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE cannula ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
Patients treated with Juvéderm Voluma XC to correct infraorbital hollows reported high satisfaction rates and experienced low rates of adverse events, according to a study. A retrospective ...
JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...
IRVINE, Calif., Jan. 18, 2023 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM ® VOLUX™ XC. The long-lasting ...
Consumers and new patients who receive aesthetic treatment from the JUVÉDERM ® Collection of Fillers, can also enroll in Allē, the Allergan Aesthetics loyalty rewards program to unlock access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback